Use of Bone-Marrow Derived Stem Cells to Treat Ischemia
AssigneeCaritas St. Elizabeth's Medical Center of Boston, Inc.
InventorDouglas W. Losordo
Life of this patent
Estimating the term…
Abstract
Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible levels of markers of other known stem cells isolated from bone marrow. These cells can be expanded in vitro and formulated into cellular compositions and grafts capable of differentiating into components of functional new blood vessels when directly administered into ischemic limb tissue.
Claims17
A method for preventing, treating or reducing the severity of tissue ischemia in a mammal having or prone to having ischemic tissue, the method comprising administering to the mammal a therapeutically effective amount of a cellular composition or graft comprising an isolated bone marrow-derived stem cell (BMSC), the cell having an undetectable level of a cell marker selected from the group consisting of:
- CD90, CD117, CD34, CD113, FLK-1, tie-2, Oct 4, GATA-4, NKx2.5, Rex-1, CD105, CD117, CD133, MHC class I receptor and MHC class II receptor, as determined by a cell marker detection assay.
A method for inducing a functional new blood vessels in a tissue of a mammal comprising administering to the mammal a therapeutically effective amount of a cellular composition or graft comprising an isolated bone marrow derived stem cell (BMSC), the cell having an undetectable level of a cell marker selected from the group consisting of:
- CD90, CD117, CD34, CD113, FLK-1, tie-2, Oct 4, GATA-4, NKx2.5, Rex-1, CD105, CD117, CD133, MHC class I receptor and MHC class II receptor, as determined by a cell marker detection assay.
A method for decreasing apoptosis due to ischemia in a tissue of a mammal comprising administering a therapeutically effective amount of a cellular composition or graft comprising an isolated bone marrow derived stem cell (BMSC), the cell having an undetectable level of a cell marker selected from the group consisting of:
- CD90, CD117, CD34, CD113, FLK-1, tie-2, Oct 4, GATA-4, NKx2.5, Rex-1, CD105, CD117, CD133, MHC class I receptor and MEC class II receptor, as determined by a cell marker detection assay.
A method for stimulating production of an angiogenic factor in a mammal comprising administering a therapeutically effective amount of a cellular composition or graft comprising an isolated bone marrow derived stem cell (BMSC), the cell having an undetectable level of a cell marker selected from the group consisting of:
- CD90, CD117, CD34, CD113, FLK-1, tie-2, Oct 4, GATA-4, NKx2.5, Rex-1, CD105, CD117, CD133, MHC class I receptor and MHC class II receptor, as determined by a cell marker detection assay.
Dependencies are inferred from the claim text.